Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study

JAMA Neurology
Rodolfo SavicaMichelle M Mielke

Abstract

To our knowledge, a comprehensive study of the survival and causes of death of persons with synucleinopathies compared with the general population has not been conducted. Understanding the long-term outcomes of these conditions may inform patients and caregivers of the expected disease duration and may help with care planning. To compare survival rates and causes of death among patients with incident, clinically diagnosed synucleinopathies and age- and sex-matched referent participants. This population-based study used the Rochester Epidemiology Project medical records-linkage system to identify all residents in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010. A movement-disorders specialist reviewed the medical records of each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy. For each confirmed patient, an age- and sex-matched Olmsted County resident without parkinsonism was also identified. We determined the age- and sex-adjusted risk of death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of death. Of the 461 patients with synucleinopathies, 279 (60.5%) were men, and of the 452 referent part...Continue Reading

Citations

Oct 7, 2017·Journal of Alzheimer's Disease : JAD·Kurt A Jellinger
Jan 23, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Rodolfo SavicaJames H Bower
Oct 6, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Avner ThalerAnat Mirelman
Mar 8, 2018·BMC Medicine·Kurt A Jellinger, Amos D Korczyn
May 10, 2019·Acta Neurologica Scandinavica·Radu ConstantinescuMarkus Axelsson
Jun 2, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Shemonti HasanRodolfo Savica
Apr 13, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Maria Fiorella ContarinoJacobus J van Hilten
Dec 26, 2018·Journal of Parkinson's Disease·E Ray DorseyBastiaan R Bloem
Sep 12, 2020·Biomarker Insights·Elena CamporesiHenrik Zetterberg
Jul 27, 2017·The American Journal of Hospice & Palliative Care·Julia StruppHeidrun Golla
Nov 17, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Luca VignatelliUNKNOWN ParkLink Bologna group
Mar 16, 2021·Journal of Parkinson's Disease·Emanuele CamerucciRodolfo Savica
Aug 14, 2019·Mayo Clinic Proceedings·Rodolfo SavicaMichelle M Mielke
Jul 10, 2020·CNS & Neurological Disorders Drug Targets·Nor H M NajibSeong L Teoh
Aug 26, 2021·Movement Disorders : Official Journal of the Movement Disorder Society·Janis M MiyasakiUNKNOWN Task Force on Palliative Care of the International Parkinson and Movement Disorder Society
May 21, 2021·Nursing·Wendi Rank

❮ Previous
Next ❯

Related Concepts

Related Feeds

Epidemiology of Aging

This feed focuses on epidemiology of aging and aging-related conditions, including Alzheimer’s disease, dementia, and age-associated cognitive impairment. Here is the latest research.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.